arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

KYNTRA BIO, INC.

KYNB
$3.72 ▼ -0.40 (-9.82%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
52 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bullish
auto_awesome

Analytical Summary

KYNTRA BIO, INC. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $15.1M
Dividend Yield —
Revenue Growth N/M
Op. Margin None
ROIC 46.1% ↗
FCF / Share $-0.99 ↗
Trailing P/E 1.3x
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$-1.47M
↓ -139.4% —
Net Income Profit after all expenses
$11.97M
↑ +178.8% —
Operating Margin Operating profit as % of sales
-369.7%
↓ -62.5% —
FCF / Share Free cash flow per share
$-0.99
↑ +71.3% —
Long-Term Debt Long-term obligations
$75.00M
— 0.0% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
3
Financial Health ↑
68
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 52 quarters